Novel biomarkers prediciting long-term survival in breast cancer. by Karlsson, Elin
Novel biomarkers predicting long-term survival in breast 
cancer 
 
Akademisk avhandling 
 
som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin vid 
Göteborgs universitet kommer att offentligen försvaras i hörsal Ivan Ivarsson, 
Medicinaregatan 3B, fredagen den 5 juni 2009 kl. 13.00 
 
av 
Elin Karlsson 
 
Fakultetsopponent: associate professor Bassem Haddad 
Lombardi comprehensive cancer centre, Georgetown University 
 
 
Avhandlingen baseras på följande arbeten: 
 
I  Karlsson E., Danielsson A., Delle U., Olsson B., Karlsson P., Helou K.
 Chromosomal changes associated with clinical outcome in lymph node-
 negative breast cancer    
 Cancer Genetics and Cytogenetics 2007;172(2):139-46 
  
II Karlsson E., Delle U., Danielsson A., Parris T., Olsson B., Karlsson P., 
 Helou K.      
 High-resolution genomic profiling to predict 10-year survival in node-
 negative breast cancer    
 Manuscript 2009 
 
III Karlsson E., Delle U., Danielsson A., Olsson B., Abel F., Karlsson P., 
 Helou K.     
 Gene expression variation to predict 10-year survival in lymph-node-
 negative breast cancer    
 BMC Cancer, 2008;8(1):254 
 
IV Karlsson E., Kovács A., Delle U., Lövgren K., Danielsson A., Parris T., 
Brennan D., Jirström K., Karlsson P., Helou K.  
Up-regulation of cell cycle arrest protein BTG2 correlates with increased 
survival in breast cancer    
Manuscript 2009 
 
 
 
       
 
 
Novel biomarkers predicting long-term survival in breast 
cancer 
 
Elin Karlsson 
Department of Oncology, Institute of Clinical Sciences, 
The Sahlgrenska academy at University of Gothenburg, Sweden 
 
 
ABSTRACT 
Breast cancer is the most common malignancy among women, affecting over a 
million women worldwide every year. During the last decades, there has been a 
dramatic increase in the survival rates due to earlier detection and improved 
treatment. Breast cancer treatment today is getting more and more targeted, but still, 
many patients are being overtreated, and some undertreated. Therefore, the need for 
additional complementary prognostic markers is urgent. In this thesis, molecular 
differences in tumours from breast cancer survivors and deceased patients have been 
explored on the DNA, RNA and protein levels. The major findings include 
differences on the genomic level between lymph node-negative 10-year survivors 
and deceased patients; gains at 4q, 5q31-5qter, 6q12-6q16 and 12q14-12q22 and losses 
at 8p21.2-8p21.3, 8p23.1-8p23.2, 17p, 18p, Xp21.3, Xp22.31-Xp22.33 and Xq were 
significantly more frequent in tumours from deceased patients compared to tumours 
from 10-year survivors. Gains at 1q25.2-1q25.3 and 1q31.3-1q41 were more common 
in tumours from 10-year survivors. In addition, a gene signature consisting of 51 
genes was generated. The expression profile of these 51 genes predicted clinical 
outcome in our material of node-negative patients as well as in an external tumour 
material with good accuracy. The protein expression of four genes (ADIPOR1, 
ADORA1, BTG2 and CD46) that differed between the survival groups, both in DNA 
copy number alterations and in gene expression, was explored in a larger 
independent cohort of breast cancer patients. The protein expression of BTG2 
significantly more frequent in tumours from 5-year survivors compared to tumours 
from deceased patients. This finding indicates expression of BTG2 as a possible 
prognostic biomarker. Furthermore, the prognostic biomarkers found in this work, 
may in the future facilitate the prognosis as well as predict course of treatment for 
breast cancer patients, following extensive validation.  
 
ISBN 978-91-628-7787-3                  Göteborg 2009 
